Benzinga | Aug 27, 2020 06:42AM EDT

Citigroup Initiates Coverage On Horizon Therapeutics with Buy Rating, Announces Price Target of $112

Citigroup analyst Navann Ty initiates coverage on Horizon Therapeutics (NASDAQ:HZNP) with a Buy rating and announces Price Target of $112.